{Reference Type}: Journal Article
{Title}: Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes.
{Author}: Pouget JG;Gonçalves VF;Nurmi EL;P Laughlin C;Mallya KS;McCracken JT;Aman MG;McDougle CJ;Scahill L;Misener VL;Tiwari AK;Zai CC;Brandl EJ;Felsky D;Leung AQ;Lieberman JA;Meltzer HY;Potkin SG;Niedling C;Steimer W;Leucht S;Knight J;Müller DJ;Kennedy JL;
{Journal}: Pharmacogenomics
{Volume}: 16
{Issue}: 1
{Year}: Jan 2015
{Factor}: 2.638
{DOI}: 10.2217/pgs.14.158
{Abstract}: <B>OBJECTIVE: </B>TSPO is a neuroinflammatory biomarker and emerging therapeutic target in psychiatric disorders. We evaluated whether TSPO polymorphisms contribute to interindividual variability in schizophrenia, antipsychotic efficacy and antipsychotic-induced weight gain.<BR><B>METHODS: </B>We analyzed TSPO polymorphisms in 670 schizophrenia cases and 775 healthy controls. Gene-gene interactions between TSPO and other mitochondrial membrane protein-encoding genes (VDAC1 and ANT1) were explored. Positive findings were evaluated in two independent samples (Munich, n = 300; RUPP, n = 119).<BR><B>RESULTS: </B>TSPO rs6971 was independently associated with antipsychotic-induced weight gain in the discovery (puncor = 0.04) and RUPP samples (p = 3.00 × 10(-3)), and interacted with ANT1 rs10024068 in the discovery (p = 1.15 × 10(-3)) and RUPP samples (p = 2.76 × 10(-4)).<BR><B>CONCLUSIONS: </B>Our findings highlight TSPO as a candidate for future investigations of antipsychotic-induced weight gain, and support the involvement of mitochondrial membrane components in this serious treatment side effect.